Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

iScience

- PMLiVE

Moderna and Merck announce data from melanoma combination therapy study

Skin cancer is one of the most common cancers in the US, with melanoma accounting for the majority of skin cancer deaths

- PMLiVE

NHS programme to give melanoma patients fast-track access to skin cancer vaccine

The phase 2 study will evaluate Scancell's iSCIB1+ in patients with advanced unresectable melanoma

regeneron headquarters

Regeneron shares positive phase 3 results for Libtayo in high-risk skin cancer

Approximately 1.8 million cases of cutaneous squamous cell carcinoma are diagnosed in the US every year

- PMLiVE

British Skin Foundation receives £10,000 donation from Circle Health Group

The healthcare provider’s previous donation is supporting research into early melanoma detection

- PMLiVE

Merck shares positive ten-year results for Keytruda in advanced melanoma

More than 100,640 cases of the skin cancer are expected to be diagnosed in the US this year

- PMLiVE

BioNTech shares promising results for mRNA immunotherapy candidate in advanced melanoma

Melanoma is currently responsible for around 58,000 deaths globally every year

- PMLiVE

Moderna/Merck share positive three-year results for investigational skin cancer vaccine

More than 100,000 new cases of melanoma are expected to be diagnosed in the US in 2024

- PMLiVE

UK scientists discover two genes offering potential drug targets against skin cancer

The three major types of skin cancer are basal cell carcinoma, squamous cell carcinoma and melanoma

- PMLiVE

FDA approves Iovance’s Amtagvi as first cellular therapy for advanced melanoma

Amtagvi is now the first one-time, individualised T cell therapy to be approved in the US for a solid tumour cancer

- PMLiVE

Medicxi forms Alys Pharma with six dermatology-focused companies with $100m

Alys will keep its component companies separate to focus on their platforms

- PMLiVE

Bristol Myers Squibb’s Opdualag approved by MHRA for advanced melanoma

Approximately 17,000 cases of melanoma are diagnosed in the UK every year

- PMLiVE

Bristol Myers Squibb’s Opdivo approved by FDA for expanded melanoma use

More than 97,000 cases of melanoma are expected to be diagnosed in the US in 2023

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links